GNMLF (Genomma Lab InternacionalB de CV) Cyclically Adjusted Revenue per Share: $0.93 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GNMLF Genomma Lab Internacional SAB de CV GNMLF
56 GF Score
Price $0.84
GF Value $0.91
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Genomma Lab InternacionalB de CV Cyclically Adjusted Revenue per Share?

Genomma Lab InternacionalB de CV GNMLF 56 Cyclically Adjusted Revenue per Share is $0.93 as of Mar. 2026. GuruFocus rates GNMLF with a GF Score™ of 56/100 and a GF Value™ of $0.91 (Fairly Valued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Genomma Lab InternacionalB de CV's adjusted revenue per share for the three months ended in Mar. 2026 was $0.238. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.93 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Genomma Lab InternacionalB de CV's average Cyclically Adjusted Revenue Growth Rate was 4.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 4.70% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 6.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Genomma Lab InternacionalB de CV was 9.10% per year. The lowest was 4.70% per year. And the median was 8.20% per year.

As of today (2026-07-16), Genomma Lab InternacionalB de CV's current stock price is $0.8368. Genomma Lab InternacionalB de CV's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $0.93. Genomma Lab InternacionalB de CV's Cyclically Adjusted PS Ratio of today is 0.90.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Genomma Lab InternacionalB de CV was 1.86. The lowest was 0.76. And the median was 1.32.


Genomma Lab InternacionalB de CV  (OTCPK:GNMLF) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Genomma Lab InternacionalB de CV's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.8368/0.93
=0.90

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Genomma Lab InternacionalB de CV was 1.86. The lowest was 0.76. And the median was 1.32.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Genomma Lab InternacionalB de CV Cyclically Adjusted Revenue per Share Related Terms


Genomma Lab InternacionalB de CV Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Genomma Lab InternacionalB de CV's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genomma Lab InternacionalB de CV Cyclically Adjusted Revenue per Share Chart

Genomma Lab InternacionalB de CV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.70 0.79 0.98 0.88 1.08

Genomma Lab InternacionalB de CV Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.00 0.99 1.09 1.08 0.93

GNMLF vs ZTS, UTHR, VTRS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genomma Lab InternacionalB de CV Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Genomma Lab InternacionalB de CV's Cyclically Adjusted PS Ratio falls into.


GNMLF
56GF Score
Genomma Lab Internacional SAB de CV GNMLF
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genomma Lab InternacionalB de CV Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Genomma Lab InternacionalB de CV's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.238/166.0400*166.0400
=0.238

Current CPI (Mar. 2026) = 166.0400.

Genomma Lab InternacionalB de CV Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.146 101.905 0.238
201609 0.144 103.084 0.232
201612 0.147 105.002 0.232
201703 0.162 108.063 0.249
201706 0.154 108.339 0.236
201709 0.162 109.628 0.245
201712 0.140 112.114 0.207
201803 0.158 113.505 0.231
201806 0.142 113.373 0.208
201809 0.140 115.130 0.202
201812 0.156 117.530 0.220
201903 0.154 118.050 0.217
201906 0.163 117.848 0.230
201909 0.153 118.581 0.214
201912 0.168 120.854 0.231
202003 0.140 121.885 0.191
202006 0.155 121.777 0.211
202009 0.152 123.341 0.205
202012 0.171 124.661 0.228
202103 0.171 127.574 0.223
202106 0.191 128.936 0.246
202109 0.193 130.742 0.245
202112 0.199 133.830 0.247
202203 0.201 137.082 0.243
202206 0.214 139.233 0.255
202209 0.224 142.116 0.262
202212 0.220 144.291 0.253
202303 0.220 146.472 0.249
202306 0.264 146.272 0.300
202309 0.245 148.446 0.274
202312 0.219 151.017 0.241
202403 0.267 152.947 0.290
202406 0.268 153.551 0.290
202409 0.274 155.246 0.293
202412 0.229 157.378 0.242
202503 0.221 158.761 0.231
202506 0.255 160.180 0.264
202509 0.248 161.030 0.256
202512 0.228 163.190 0.232
202603 0.238 166.040 0.238

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $0.93 mean?
Genomma Lab InternacionalB de CV (GNMLF) has a Cyclically Adjusted Revenue per Share of $0.93 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Genomma Lab InternacionalB de CV and its competitors.
Is Genomma Lab InternacionalB de CV's Cyclically Adjusted Revenue per Share too high?
Genomma Lab InternacionalB de CV's current Cyclically Adjusted Revenue per Share is $0.93. Overall, Genomma Lab InternacionalB de CV has a GF Score™ of 56/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Genomma Lab InternacionalB de CV's Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Genomma Lab InternacionalB de CV's Cyclically Adjusted Revenue per Share of $0.93 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Genomma Lab InternacionalB de CV and its competitors. Genomma Lab InternacionalB de CV's current Cyclically Adjusted Revenue per Share is $0.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomma Lab InternacionalB de CV stock overvalued right now?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV (GNMLF) is currently considered Fairly Valued. The stock's GF Value™ is $0.91, compared to a current price of $0.84 — trading 8% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $0.93. Genomma Lab InternacionalB de CV's overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Genomma Lab InternacionalB de CV (GNMLF), the current Cyclically Adjusted Revenue per Share is $0.93 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genomma Lab InternacionalB de CV (GNMLF) Overvalued in 2026?

Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV stock appears to be undervalued. The current stock price of $0.84 is trading 8% below its estimated GF Value™ of $0.91. GuruFocus considers Genomma Lab InternacionalB de CV to be Fairly Valued.

Key valuation signals for GNMLF:

  • Cyclically Adjusted Revenue per Share: $0.93
  • GF Value™: $0.91 vs. price of $0.84 (8% below fair value)
  • GF Score™: 56/100 with 4 warning signs

No single metric tells the full story. See the GNMLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Genomma Lab InternacionalB de CV Business Description

Other Exchanges LABB:MexicoGEKA:Germany
Address Avenida Antonio Dovali Jaime, Number 70, Tower C, Floor 2, Office A. Colonia Santa Fe, Del. Alvaro Obregon, Mexico, MEX, MEX, CP 01210
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
56GF Score

Get the complete analysis for GNMLF

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.84
Price
$0.91
GF Value